Zomig, which contains the active ingredient zolmitriptan, was first approved by the U.S. Food and Drug Administration (FDA) in 1997 for the treatment of migraine. It was developed by AstraZeneca and has since been made available in various formulations, including tablets and nasal spray. The medication is part of a class of drugs known as triptans, specifically designed to treat acute migraine attacks.
zanax combined w-zomig
Zomig (zolmitriptan) is a serotonin receptor agonist, used to treat migraines.
Zomig (zolmitriptan) has a half-life of about 3 hours, meaning it takes around 18 hours to be mostly cleared from your system. However, individual factors such as metabolism and dose can affect how long it stays in the body.
Zomig is a prescription medicine, and as such needs to be taken as directed by your doctor who knows your personal medical history as well as the potential implications of taking this medicine. Never change your medicine protocol without first talking to your doctor for detailed instructions.
To over come market ris l
ergotamine (Cafergot), naratriptan (Amerge), sumatriptan (Imitrex), rizatriptan (Maxalt), almotriptan (Axert), and zolmitriptan (Zomig).
2003
1991
1957
1967
1998
December 31st 1998